Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC

Introduction: Biological therapies such as bevacizumab have improved survival in patients with NSCLC. This study was conducted to confirm the equivalent efficacy of the biosimilar candidate BI 695502 to the bevacizumab reference product (RP). Methods: In this phase 3, multicenter, randomized, double...

Full description

Bibliographic Details
Main Authors: Edward S. Kim, MD, Sigrid Balser, PhD, Klaus B. Rohr, PhD, Ragna Lohmann, PhD, Bernd Liedert, PhD, Dorothee Schliephake, PhD
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:JTO Clinical and Research Reports
Subjects:
BI 695502
Bevacizumab
Biosimilar
Non–small-cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321001077

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321001077

Similar Items